Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Characterizing the Effects of Oral Doses of Rifampin on Intestinal Transporters

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: LIU, Shufang (University of California San Francisco, Bioengineering and Therapeutic Sciences, San Francisco, United States)
  • Co-author(s): Shufang Liu: Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, United States
    Hideaki Okochi: Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, United States
    Leslie Benet: Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, United States
  • Abstract:

    Backgrounds

    Rifampin (RIF) is well recognized as an inducer of P-gp upon multiple dosing, and a concentration dependent inhibitor of hepatic OATPs following a single dose, which have been characterized in our laboratory. A recent in vitro study suggests that RIF also inhibits P-gp with an IC50 of 29 μM.

    Aims

    To investigate the effects of oral RIF

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses